| Literature DB >> 30200668 |
Seong-Ah Shin1, Sun Young Moon2, Woe-Yeon Kim3, Seung-Mann Paek4, Hyun Ho Park5, Chang Sup Lee6.
Abstract
A variety of malignant cancers affect the global human population. Although a wide variety of approaches to cancer treatment have been studied and used clinically (surgery, radiotherapy, chemotherapy, and immunotherapy), the toxic side effects of cancer therapies have a negative impact on patients and impede progress in conquering cancer. Plant metabolites are emerging as new leads for anti-cancer drug development. This review summarizes these plant metabolites with regard to their structures and the types of cancer against which they show activity, organized by the organ or tissues in which each cancer forms. This information will be helpful for understanding the current state of knowledge of the anti-cancer effects of various plant metabolites against major types of cancer for the further development of novel anti-cancer drugs.Entities:
Keywords: anti-cancer drug; cancer; metabolite; plant
Mesh:
Substances:
Year: 2018 PMID: 30200668 PMCID: PMC6163735 DOI: 10.3390/ijms19092651
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Structure of phenolic compounds.
Figure 2Structure of terpenoids.
Figure 3Structure of nitrogen-containing alkaloids and sulfur-containing compounds.
Structural classification of active metabolites with anticancer activity.
| Class | Active Metabolite | Structure |
|---|---|---|
|
| Curcumin |
|
| Decursin |
| |
| Decursinol |
| |
| Decursinol angelate |
| |
| Dichamanetin |
| |
| Epigallocatechin gallate (EGCG) |
| |
| Fisetin |
| |
| Genistein |
| |
| Hydroxycinnamic acid |
| |
| Hypericin |
| |
| Quercetin |
| |
|
| Resveratrol |
|
| Punicalagin (PC) |
| |
| γ-viniferin |
| |
|
| Asiatic acid |
|
| Ailanthus excelsa chloroform extract-1 (AECHL-1) |
| |
| Amooranin (AMR) |
| |
| Auraptene (AUR) |
| |
| Betulinic acid (BA) |
| |
| Celastrol |
| |
| Curcubitane-type triterpenoids |
| |
| Dammarane triterpenoid |
| |
| Lupeol |
| |
| Meliavolkenin |
| |
| Pomolic acid |
| |
| Pristimerin |
| |
| Remangilones A |
| |
| Remangilones C |
| |
| Tirucallane-type triterpenoids |
| |
| Ursolic acid |
| |
| β-carotene |
| |
|
| Allicin |
|
| Benzyl isothiocyanate (BITC) |
| |
| Diallyl sulfide (DAS) |
| |
| Indole-3-carbinol (I3C) |
| |
| Phenethyl isothiocyanate (PEITC) |
| |
| Sulforaphane (SFN) |
| |
| Tomatine |
| |
| 6-MSITC |
|
Anti-cancer effects of active metabolites from plants in different types of cancer.
| Type of Cancer | Active Metabolites | In Vitro or In Vivo Effects | IC50 & Effective Concentration (EC) (μM). | Ref. |
|---|---|---|---|---|
|
| Dichamanetin | Induction of ROS and cell cycle arrest in HT-29 colon cancer cells | IC50: 13.8 | [ |
| GAP | Suppression of colon carcinogenesis in DSS mice | EC: 0.01 % or 0.05 % in diet | [ | |
| Auraptene | Inhibition of the growth of colon cancer cells and suppression of colonosphere formation | EC: 10 | [ | |
| Curcumin | Suppression of the oncogenicity of human colon cancer cells and the growth of HCT-116 tumor xenografts | EC: 10 | [ | |
| Genistein | Inhibition of cell proliferation and induction of apoptosis in HCT 116 and LoVo cells | EC: 135 | [ | |
| Inhibition of metastasis in colorectal cancer cell implanted nude mice | ||||
| I3C+Genistein | Induction of apoptosis in HT 29 colon cancer cells | I3C EC: 300 | [ | |
| BITC | Suppression of viability in HCT 116 colon cancer cells | EC: 5–20 | [ | |
| SFN | Induction of apoptosis and inhibition of proliferation in HT 29 colon cancer cells | EC: 5–20 | [ | |
| PEITC | Reduction of colon carcinogenesis in AOM/DSS induced mice | EC: 0.12 % in diet | [ | |
| 6-MSITC | Induction of apoptosis in HCT 116 colon cancer cells | IC50: 0.92–10.01 | [ | |
|
| Resveratrol | Inhibition of proliferation in gastric cancer cells | EC: 50–200 | [ |
| SFN | Prevention of benzo[a]pyrene-induced stomach tumors in mice | EC: 1.33 mg per mouse | [ | |
| PEITC | Induction of cell cycle arrest and apoptosis in gastric cancer cells MKN74 and Kato-III | EC: 17.8 | [ | |
| Inhibition of migration and invasion in AGS gastric cancer cells | ||||
| BITC | Inhibition of migration and invasion in AGS gastric cancer cells | EC: 0.25–0.5 | [ | |
| Curcumin | Inhibition of proliferation in SGC-7901 gastric cancer cells | EC: 15–60 | [ | |
| Reduction of xenograft tumor growth in mice | ||||
| Reduction of LVD in gastric cancer bearing nude mice | ||||
| Quercetin | Induction of apoptosis in BGC-823 gastric cancer cells | EC: 30–120 | [ | |
| Allicin | Inhibition of gastric cancer cell growth | EC: 184.88 | [ | |
|
| EGCG | Induction of cell cycle arrest and apoptosis in lung cancer cells | IC50: 70 | [ |
| BITC | Inhibition of growth in A549 lung cancer cells | EC: 10 | [ | |
| Inhibition of tumorigenesis in PAH-induced A/J mice | ||||
| PEITC | Induction of apoptosis in NSCLC cells | EC: 12.5–20 | [ | |
| SFN | Induction of apoptosis in NSCLC cells | EC: 10 | [ | |
| Alleviation of carcinogenic lung in B(a)P induced lung cancer bearing mice | ||||
| I3C | Induction of apoptosis in A549 lung adenocarcinoma cells in combination with TRAIL | EC: 100–500 | [ | |
| Inhibition of progression of tobacco carcinogen induced lung adenocarcinoma progression | ||||
| Induction of cell cycle arrest and apoptosis in A549 lung cancer cells | ||||
| Inhibition of NNK-induced lung tumors in combination with silibinin in mice | ||||
| Genistein | Inhibition of carcinogenesis in mice with VC-induced lung cancer | IC50: 81 | [ | |
| Inhibition of cell proliferation and induction of apoptosis in combination with gefitinib in H1975 NSCLC cells | ||||
| Fisetin | Inhibition of cell growth and induction of apoptosis in combination with chemotherapeutic agents in H460 NSCLC cells | IC50: 59 | [ | |
| Inhibition of cell viability and colony-forming activity in A549 NSCLC cells | ||||
| Inhibition of the invasion and migration of A549 NSCLC cells | ||||
| Inhibition of lung carcinogenesis in B(a)P-induced mice | ||||
| Inhibition of angiogenesis and tumor growth in Lewis lung carcinoma bearing mice | ||||
| Punicalagin | Anti-proliferative effects on A549 and H1299 NSCLC cells | EC: 11.52–184.3 | [ | |
| Curcumin | Inhibition of cell growth and invasion in NSCLC cells | EC: 30 | [ | |
|
| Tomatine | Induction of cell cytotoxicity and apoptosis in MCF-7 breast cancer cells | IC50: 7.07 | [ |
| I3C | Increasing apoptotic cell death and decreasing the proliferation of the ERα-positive breast cancer cells | IC50: 204 | [ | |
| Curcubitane-type triterpenoids | Inhibition of cell growth and induction of apoptosis in human breast cancer cells | EC: 0.5–35.7 | [ | |
| Dammarane triterpenoids | Cytotoxicity against breast cancer cells | EC: 20.97 | [ | |
| Pristimerin | Induction of apoptosis in MDA-MB-231 breast cancer cells | EC: 1–3 | [ | |
| Celastrol | Inhibition of cell growth and invasion and induction of apoptosis in W256 breast cancer cells | EC: 1 | [ | |
| Meliavolkenin | Cytotoxicity against MCF7 breast cancer cells | EC: 6.05 | [ | |
| Betulinic acid | Induction of anti-proliferation in MCF7 and T47D breast cancer cells | IC50: 2.4 | [ | |
| Lupeol | Inhibition of MDA-MB-231 ERα-negative cell proliferation | EC: 1–30 | [ | |
| Ursolic acid | Inhibition of proliferation and induction of apoptosis in MCF7 cells | IC50: 3.26 | [ | |
| Asiatic acid | Inhibition of cell growth and induction of apoptosis in MCF7 and MDA-MB 231 cells | IC50: 5.95–8.12 | [ | |
| Remangilones A and C | Cytotoxicity against MDA-MB-231 and MDA-MB-435 cells | RemangilonesA IC50: 6.6–8.5 | [ | |
| Amooranin | Induction of apoptosis and suppression of cell growth in MDA-468 and MCF7 cells | IC50: 3.82-7.22 | [ | |
| Tirucallane-type triterpenoids | Cytotoxicity against MCF7 cells | IC50: 41.33–86.14 | [ | |
| AECHL-1 | Regression of MCF7 xenograft tumors in nude mice | EC: 5–100 | [ | |
| Curcumin | Anti-proliferation of BPA-induced MCF7 cells | EC: 1 | [ | |
| Resveratrol | Reduction of cell viability in breast cancer cells (MCF-7, ZR-75-1, and MDA-MB-231) | IC50: 67.6–82.2 | [ | |
| Hydroxycinnamic acid | Inhibition of migration in MCF-7 and MDA-MB-231 cells | IC50: 75.71 | [ | |
| Dichamanetin | Induction of ROS and cell cycle arrest in MDA-MB-231 cells | EC: 8.7 | [ | |
|
| Decursinol | Suppression of tumor growth in mice with xenografted DU145 and PC3 prostate cancers | EC: 4.5 mg per mouse | [ |
| Decursin & Decursinol angelate | Inhibition of prostate epithelium growth in the TRAMP model | EC: 3 mg per mouse | [ | |
| Resveratrol & γ-viniferin | Inhibition of the growth of LNCaP prostate cancer cell | Resveratrol IC50: 10.23-228.3 | [ | |
| Fisetin | Inhibition of cell growth and proliferation in PU3 and DU145 cells | EC: 20–80 | [ | |
| Genistein | Inhibition of cellular invasion in in vitro prostate cancer and in vivo metastasis formation in mice with xenografts of PC3-M prostate cancer | EC: 10 | [ | |
| Curcumin | Inhibition of CAF-induced EMT and invasion in PC3 cells | EC: 25 | [ | |
| SFN and I3C | Induction of cell cycle arrest and apoptosis of PC3, LNCaP, and DU145 cells in vitro | SFN EC: 40 | [ | |
|
| Hypericin | Attenuation of MTX cytotoxicity in HL-60 promyelocytic leukemia cells | EC: 0.1–0.5 | [ |
| Resveratrol | Induction of DNA breakage in human peripheral lymphocytes | EC: 10–75 | [ | |
| EGCG | Induction of apoptotic death in Ramos B lymphoblastoid cells | EC: 60–100 | [ | |
| I3C | Inhibition of cell growth and induction of apoptosis in pre-B acute lymphoblastic leukemia cells | EC: 60 | [ | |
|
| Diallyl sulfide | Reduction of DNA strand breaks in DMBA induced mouse skin | EC: 25 | [ |
| Pomolic acid | Cytotoxic effects against M-14 melanoma cells | EC: 14.6 | [ | |
|
| β-carotene | Inhibition of tumor growth in nude mice with xenografts of Eca109 ESCC cell xenografts | EC: 30 | [ |
| EGCG | Induction of cell cycle arrest and apoptosis in YCU-N861 and YCU-H891 HNSCC cells | EC: 30–60 | [ |